Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Comment by CurlyMickon Aug 23, 2014 9:59am
139 Views
Post# 22871652

RE:Dog days of summer, yawn

RE:Dog days of summer, yawnYes George....

We've all flipped this over the long haul, but with much better success in the past on less meaningful news than the recent news. While I appreciate the flipping chances, I abhor the dismal results, or more correctly ZERO results after the old news flashes. You'll remember....

the US military news, the Pacific Vet Sales alliance, the cleaning solutions company out of Montreal selling KBI, all to create revenue. Result? Every three months we give thousands of more shares to Mr. Reanud. How about that "successful launch of StrixNB!" Nope no revenue.

I truly do understand that proving efficacy takes time, but that's moreso true if you nickle and dime your research. I hope that as part of the DD exercise some significant amount of and meaningful testing is being done with significant cash from Bayer (or whoever is the pharma co). BUT according to Kane, the current DD involves a potential animal and pet deal. With all the competing products out there now, this Big Pharma company is going to have to have some real compelling reason to proceed to that market.

If as alleged DisersinB is potentially superior to other biofilm disruptors, then the largest amount of money (revenue) will come from human applications. IMHO, Kane seems to be beating around the bush and not chopping into it to expose the real potential value. Personally, since time is money and given that there will always be a new and improved product that will come out and again be better than even DispersinB, I would rather see some bold moves now. 

Sitting on this with failures all the way along makes people believe that poor performance is simply the norm for a small biotech film. Such is not true of the few biotech stars with guts, vision and an allegedly solid product. 

The fact that the intial share price most of us entered at is higher than the current SP is relevant and shouldn't be so easily dismissed because we also flipped KNE or as most of us have done, averaged down. The SP is an indication that Kane is stagnating and has done so over years due to its failure to deliver on news. 

All with the utmost of respect for your opinion...and all IMHO.

Curly
Bullboard Posts